US 11,666,528 B2
Drug implants containing enzalutamide and methods of use thereof
Maithili Rairkar, San Francisco, CA (US); Pujan Desai, Oakland, CA (US); Carlos Schuler, San Francisco, CA (US); Keith Hall, San Francisco, CA (US); Pamela Munster, Hillsborough, CA (US); John Maroney, San Francisco, CA (US); and Scott Thomas, San Francisco, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US); and Alessa Therapeutics, Inc., San Carlos, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US); and Alessa Therapeutics, inc., San Carlos, CA (US)
Filed on Apr. 25, 2022, as Appl. No. 17/728,702.
Claims priority of provisional application 63/179,915, filed on Apr. 26, 2021.
Prior Publication US 2023/0080240 A1, Mar. 16, 2023
Int. Cl. A61K 9/00 (2006.01); A61K 47/34 (2017.01); A61K 31/4166 (2006.01)
CPC A61K 9/0024 (2013.01) [A61K 31/4166 (2013.01); A61K 47/34 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A drug implant comprising:
a) a biocompatible, non-biodegradable polymer matrix; and
b) enzalutamide dispersed in the biocompatible, non-biodegradable polymer matrix.